← All indications
Papilloma
A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)
Subtype terms (1)
More specific conditions that are subtypes of Papilloma in the MeSH hierarchy.
- Papilloma, Inverted
16 drugs (11 approved, 5 experimental)
Drugs by status
Phase 3 trials (1)
Phase 2 trials (5)
Phase 1 trials (9)
Organizations
Organization Involved with Phase 4 Indications (18)
- ViiV Healthcare
- Merck
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- United States Navy
- Augusta University
- Centre Hospitalier Universitaire de la Réunion
- Eastern Virginia Medical School
- Johns Hopkins University
- University of Toronto
- Janssen Pharmaceutica NV
- University of Texas, Galveston
- Free University of Brussels
- University of Wisconsin
- University of New South Wales
- State of Texas
- UNITAID
- The Physicians' Services Incorporated Foundation
Organization Involved with Phase 3 Indications (25)
- Shanghai Zerun Biotechnology Co.,Ltd
- The EMMES Corporation
- National Cancer Institute (NCI)
- National Institute of Child Health, Hungary
- AIDS Malignancy Consortium
- University of London
- Harvard University
- Hoosier Cancer Research Network
- Katholieke Universiteit Leuven
- University of Glasgow
- University of York
- University of California, San Francisco
- Institute of Hematology and Blood Transfusion, Czech Republic
- Government of Mexico
- Karolinska Institute
- Government of China
- NHMRC CCRE in Childhood and Adolescent Immunisation
- National Autonomous University of Mexico
- Charles University
- Na Homolce Hospital
- Murdoch University
- Brockhoff Foundation Australia
- Shepherd Foundation Australia
- Catalan Institute of Oncology
- Government of Tanzania
Organization Involved with Phase 2 Indications (33)
- PPD
- Eisai
- MedImmune
- Catalysis SL
- Cesa Projects International
- Immunicum AB
- Inovio Pharmaceuticals
- Nielsen BioSciences, Inc.
- Nventa Biopharmaceuticals Corporation
- Amarillo Biosciences, Inc.
- Biontech
- Genkyotex Innovation SAS
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- University of Pennsylvania
- University of Arizona
- Boston University
- Cornell University
- Eastern Cooperative Oncology Group
- ECOG-ACRIN Cancer Research Group
- Gynecologic Oncology Group
- Northwell Health
- Sanford Health
- Rutgers University
- Shenzhen Geno-Immune Medical Institute
- Stanford University
- University of Iowa
- University of Medicine and Dentistry of New Jersey
- University of California, Los Angeles
- University of Chicago
- Vanderbilt University
- +3 more
Organization Involved with Phase 1 Indications (12)
Organization Involved with Other Experimental Indications (7)